- Home
- CELC
CELC
Celcuity Inc.
as 11-26-2025 3:37pm EST
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | MINNEAPOLIS |
| Market Cap: | 3.1B | IPO Year: | 2017 |
| Target Price: | $95.29 | AVG Volume (30 days): | 916.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.67 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.58 - $103.06 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Celcuity Inc. (CELC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dalvey David | CELC | Director | Nov 21 '25 | Sell | $100.00 | 15,000 | $1,500,016.50 | 110,000 | |
| Buller Richard E | CELC | Director | Nov 20 '25 | Sell | $96.73 | 3,900 | $377,254.80 | 7,260 | |
| BAKER BROS. ADVISORS LP | CELC | 10% Owner | Sep 8 '25 | Buy | $57.12 | 170,100 | $9,571,318.56 | 703,920 |
Latest Celcuity Inc. News
CELC Breaking Stock News: Dive into CELC Ticker-Specific Updates for Smart Investing
Insider Monkey
4 days ago
Celcuity (CELC)’s Clinical Success and M&A Potential Underpin Wolfe Research’s Bullish View
MT Newswires
6 days ago
Celcuity Insider Sold Shares Worth $377,255, According to a Recent SEC Filing
Simply Wall St.
9 days ago
Celcuity (CELC) Is Up 7.6% After FDA Accepts Gedatolisib Application for Expedited Review - What's Changed
TipRanks
9 days ago
Block upgraded, Dell downgraded: Wall Street’s top analyst calls
MT Newswires
10 days ago
Celcuity Submits New Drug Application for Gedatolisib to Treat Breast Cancer
GlobeNewswire
10 days ago
Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
MT Newswires
10 days ago
HC Wainwright Downgrades Celcuity to Neutral From Buy, Adjusts PT to $94 From $77
MT Newswires
10 days ago
HC Wainwright Downgrades Celcuity to Neutral From Buy, Price Target is $94
Compare CELC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CELC Celcuity Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.